Pall Biotech to collaborate with Aetos Biologics

| By | Biosimilars, Biotechnologies, GMP Standards
0
167

Pall Corporation, a global leader in filtration, separation and purification, has announced a strategic partnership between its Pall Biotech business unit and Aetos Biologics, a biosimilar cell line development company.

The companies will collaborate to offer biosimilar manufacturing solutions to the global biosimilars market. Pall Biotech will provide access to next generation bioprocess equipment, such as the Allegro™ STR Single-use Stirred Tank Bioreactor for good manufacturing practices (GMP) manufacturing, and consumables to enable efficient biosimilar production. Aetos Biologics will provide high-quality/high-titer cell lines, and scalable manufacturing processes.

By aligning Pall Biotech equipment, including bioreactors, mixing and storage, and downstream technologies with Aetos Biologics’ cell lines and manufacturing processes, customers benefit from access to integrated solutions for expedited biosimilars development.

Located in San Francisco Bay Area, California (USA), Aetos Biologics has assembled a formidable gene to product team comprised of seasoned industry veterans experienced in biosimilar development, manufacturing, clinical trials, global regulatory requirements and successful commercialization. Aetos Biologics serves partners engaged in commercialization of biosimilars for the global market.

SOURCE: prnewswire
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.